NCT00532545

Bone Marker Changes With Teriparatide/Postmenopausal Osteoporosis

Bone Marker Changes In One Month Treatment With TERIPARATIDE (LY333334) Injections (rDNA Origin) in Men and Postmenopausal Women With Severe Osteoporosis

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 45 (actual)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 50 Years
• Healthy volunteers: Not accepted

Summary

To test the hypothesis that Teriparatide injections given 20 micrograms/daily subcutaneously, for one month, are able to produce reliable changes in the bone marker in a severe osteoporotic population

Conditions

• Osteoporosis, Post-Menopausal

Interventions

Type	Name	Description
DRUG	Teriparatide	Teriparatide 20 micrograms/daily subcutaneously

Timeline

• Start date: 2003-04-01
• Completion: 2004-04-01
• First posted: 2007-09-20
• Last updated: 2007-09-20

Locations

7 sites across 1 country: Puerto Rico